The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
Sponsor: Odonate Therapeutics, Inc.
Terminated
The Sponsor has discontinued the development of tesetaxel
Other terminated trials from Odonate Therapeutics, Inc.
- Breast Cancer · Phase PHASE3 · Jun 2021
- Breast Cancer · Phase PHASE2 · Jun 2021
- Breast Cancer · Phase PHASE2 · Jun 2021
More terminations from Odonate Therapeutics, Inc.
Other Advanced Solid Tumors trials with similar outcome
A PHASE1 clinical study on Advanced Solid Tumors, this trial is terminated or withdrawn. The trial is conducted by Odonate Therapeutics, Inc. and has accumulated 7 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 2 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — Nov 2020 [monthly]
Recruiting PHASE1
First recorded
Mar 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Odonate Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .